Horizant Tablet, Extended Release
NDC Package 53451-0101-9
Package Information
Horizant (gabapentin enacarbil) tablets is a medication used to treat moderate to severe restless legs syndrome. This formulation utilizes a tablet, extended release delivery system. Marketed by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), this product is identified by NDC 53451-0101 and is authorized under FDA application NDA022399.
Identification & Billing
- RxCUI: 1101338 - gabapentin enacarbil 600 MG Extended Release Oral Tablet
- RxCUI: 1101339 - Horizant 600 MG Extended Release Oral Tablet
- RxCUI: 1101339 - gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant]
- RxCUI: 1482820 - gabapentin enacarbil 300 MG Extended Release Oral Tablet
- RxCUI: 1482821 - Horizant 300 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53451 - Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
- 53451-0101 - Horizant
- 53451-0101-9 - 5 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
- 53451-0101 - Horizant
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (53451-0101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53451-0101-9 identifies a specific commercial package of 5 tablet, extended release in 1 bottle, plastic of Horizant, a human prescription drug labeled by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals). This tablet, extended release is formulated for oral use and contains gabapentin enacarbil as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) on May 01, 2013. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat moderate to severe restless legs syndrome. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection). This condition is called postherpetic neuralgia. Gabapentin enacarbil is changed by your body to gabapentin. Gabapentin belongs to a class of drugs known as anti-seizure or anticonvulsant drugs.
How is this Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53451010109. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.